9102
A. Banerjee et al. / Tetrahedron 69 (2013) 9096e9104
under O2 atmosphere. The progress of the reaction was monitored
by TLC. After the completion of the reaction as judged from TLC
the reaction mixture was cooled and then admixed with water
(1 mL) and the product was extracted with ethyl acetate
(2ꢁ10 mL). The organic layer was dried over anhydrous sodium
sulfate (Na2SO4), filtered and evaporated under reduced pressure.
The crude products so obtained were further purified through
silica gel column chromatograph (hexane/ethyl acetate, 9:1) to
yield the pure substituted 2-morpholinobenzo[d]thiazole
(1a0e10a0). The identity and purity of the product was further
confirmed by spectroscopic analysis. Reaction performed with
phenyl isothiocyanate (1) (1.5 mmol) and other secondary amines
(bef) (1.5 mmol) in the above mentioned method and corre-
sponding benzo[d]thiazoles (1b0ef0) were isolated and spectro-
scopically characterized.
48.4; HRMS (ESI) calcd for C17H17N3S (MþHþ) 296.1216, found
296.1214.
4.2.5. 2-(4-Benzylpiperidin-1-yl)benzo[d]thiazole (1e0). The general
procedure was followed. The product was purified by column
chromatography (10% EtOAc/hexane) to give the title compound 1e0
(215 mg, 70%) as white solid; Rf (10% EtOAc/hexane) 0.26; mp
114 ꢀC; nmax (KBr): 3061, 3024, 2937, 2920, 2851, 1595, 1539, 1492,
1444, 1388, 1324, 1278, 1258, 1172, 922, 752, 727 cmꢂ1
;
1H NMR
7.60 (t, 2H, J¼6.4 Hz, Ar. CeH), 7.32 (m, 2H, Ar.
(400 MHz, CDCl3):
d
CeH), 7.26 (d, 1H, J¼7.2 Hz, Ar. CeH), 7.18 (d, 2H, J¼8.0 Hz, Ar. CeH),
7.08 (t, 2H, J¼8.0 Hz, Ar. CeH), 4.15 (d, 2H, J¼13.2 Hz,
aliphaticeCH2e), 3.06 (t, 2H, J¼12.8 Hz, aliphaticeCH2e), 2.59 (d,
2H, J¼7.2 Hz, aliphaticeCH2e), 1.77 (d, 4H, J¼10.8 Hz,
aliphaticeCH2e), 1.37 (m, 1H, aliphatic CeH); 13C NMR (100 MHz,
CDCl3):
d 168.7, 153.0, 139.9, 130.8, 129.2, 128.4, 126.2, 126.0, 121.2,
4.2.1. 4-(Benzo[d]thiazol-2-yl)morpholine (1a0). The general pro-
cedure was followed. The product was purified by column chro-
matography (10% EtOAc/hexane) to give the title compound 1a0
(187 mg, 85%) as white solid; Rf (10% EtOAc/hexane) 0.24; mp
122 ꢀC; nmax (KBr): 2918, 2854, 1591, 1537, 1441, 1377, 1289, 1229,
120.7, 118.9, 49.0, 43.0, 38.0, 31.5; HRMS (ESI) calcd for C19H20N2S
(MþHþ) 309.0955, found 309.0959.
4.2.6. 2-Thiomorpholinobenzo[d]thiazole (1f0). The general pro-
cedure was followed. The product was purified by column chro-
matography (10% EtOAc/hexane) to give the title compound 1f0
(187 mg, 75%) as yellow gum; Rf (10% EtOAc/hexane) 0.22; nmax
(KBr): 3059, 2936, 2858, 1599, 1531, 1444, 1385, 1359, 1313, 1218,
1113, 1067, 1032, 945, 859, 756 cmꢂ1 1H NMR (400 MHz, CDCl3):
;
d
7.57 (dd, 2H, J1¼6.4 Hz, J2¼4.0 Hz, Ar. CeH), 7.27 (t, 1H, J¼8.0 Hz,
Ar. CeH), 7.07 (t, 1H, J¼7.6 Hz, Ar. CeH), 3.80 (t, 4H, J¼4.4 Hz,
aliphaticeCH2e), 3.59 (t, 4H, J¼4.4 Hz, aliphaticeCH2e); 13C NMR
1054, 1020, 899, 750 cmꢂ1; 1H NMR (400 MHz, CDCl3):
d 7.57 (d, 1H,
(100 MHz, CDCl3):
d
169.0, 152.5, 130.6, 126.1, 121.7, 120.8, 119.4,
J¼7.6 Hz, Ar. CeH), 7.52 (d, 1H, J¼8.0 Hz, Ar. CeH), 7.28 (t, 1H,
J¼8.0 Hz, Ar. CeH), 7.06 (t, 1H, J¼7.2 Hz, Ar. CeH), 3.93 (t, 4H, J¼4.8,
aliphaticeCH2e), 2.71 (t, 4H, J¼5.2 Hz, aliphaticeCH2e); 13C NMR
66.2, 48.5; Anal. Calcd for C11H12N2OS: C, 59.97; H, 5.49; N, 12.72;
Found C, 60.02; H, 5.55; N, 12.69.
(100 MHz, CDCl3):
d 168.2, 152.7, 130.8, 126.2, 121.6, 120.8, 119.2,
4.2.2. 2-(Piperidin-1-yl)benzo[d]thiazole (1b0). The general pro-
cedure was followed. The product was purified by column chro-
matography (10% EtOAc/hexane) to give the title compound 1b0
(174 mg, 80%) as white solid; Rf (10% EtOAc/hexane) 0.25; mp
96.5 ꢀC; nmax (KBr): 3063, 2939, 2922, 2848, 1590, 1535, 1440, 1385,
51.3, 26.7; Anal. Calcd for C11H12N2S2: C, 55.90; H, 5.12; N, 11.85;
found C, 55.93; H, 5.18; N, 11.79.
4.2.7. 4-(5-Chlorobenzo[d]thiazol-2-yl)morpholine (2a0). The gen-
eral procedure was followed. The product was purified by column
chromatography (10% EtOAc/hexane) to give the title compound 2a0
(198 mg, 78%) as white solid; Rf (10% EtOAc/hexane) 0.23; mp
108 ꢀC; nmax (KBr): 3051, 2978, 2930, 2902, 2855, 1737, 1587, 1530,
1437, 1375, 1325, 1279, 1234, 1142, 1110, 1070, 1035, 885, 872, 808,
1333,1287,1258,1212,1121,1009, 935, 902, 811, 761, 730, 648 cmꢂ1
;
1H NMR (400 MHz, CDCl3):
d
7.54 (d, 2H, J¼7.6 Hz, Ar. CeH), 7.25 (t,
1H, J¼5.4 Hz, Ar. CeH), 7.02 (t, 1H, J¼7.2 Hz, Ar. CeH), 3.55 (s, 4H,
aliphaticeCH2e), 1.63 (s, 6H, aliphaticeCH2e); 13C NMR (100 MHz,
CDCl3):
d
168.9, 153.0, 130.7, 125.9, 121.1, 120.6, 118.8, 49.6, 25.3,
678, 632, 603 cmꢂ1 1H NMR (400 MHz, CDCl3):
; d 7.54 (s, 1H, Ar.
24.3; Anal. Calcd for C12H14N2S: C, 66.02; H, 6.46; N, 12.83; found C,
66.08; H, 6.50; N, 12.76.
CeH), 7.49 (d, 1H, J¼8.4 Hz, Ar. CeH), 7.06 (d, 1H, J¼2.6 Hz, Ar. CeH),
3.82 (t, 4H, J¼5.0 Hz, aliphaticeCH2e), 3.61 (t, 4H, J¼5.0 Hz,
aliphaticeCH2e); 13C NMR (100 MHz, CDCl3):
d 170.1, 153.8, 132.1,
4.2.3. 2-(Pyrrolidin-1-yl)benzo[d]thiazole (1c0). The general pro-
cedure was followed. The product was purified by column chro-
matography (10% EtOAc/hexane) to give the title compound 1c0
(138 mg, 68%) as white solid; Rf (10% EtOAc/hexane) 0.22; mp
101 ꢀC; nmax (KBr): 2950, 2868, 1604, 1561, 1544, 1442, 1365, 1341,
129.0, 121.7, 121.5, 119.4, 66.3, 48.5; HRMS (ESI) calcd for
C
11H11N2OClS (MþHþ) 255.0353, found 255.0350.
4.2.8. 4-(6-Fluorobenzo[d]thiazol-2-yl)morpholine (3a0). The gen-
eral procedure was followed. The product was purified by column
chromatography (10% EtOAc/hexane) to give the title compound 3a0
(180 mg, 76%) as white solid; Rf (10% EtOAc/hexane) 0.21; mp
145 ꢀC; nmax (KBr): 3058, 2982, 2906, 2883, 2864, 2845, 1903, 1674,
1611, 1539, 1459, 1376, 1343, 1287, 1235, 1181, 1112, 1073, 1029, 948,
1317, 1276, 1258, 1175, 1120, 1069, 859, 747, 720 cmꢂ1
(400 MHz, CDCl3):
;
1H NMR
d
7.58 (d, 2H, J¼8.4 Hz, Ar. CeH), 7.28 (t, 1H,
J¼7.6 Hz, Ar. CeH), 7.03 (t, 1H, J¼7.6 Hz, Ar. CeH), 3.56 (m, 4H,
aliphaticeCH2e), 2.06 (m, 4H, aliphaticeCH2e); 13C NMR
(100 MHz, CDCl3):
d
165.5, 153.4, 130.8, 126.0, 120.8, 120.7, 118.7,
920, 844, 805, 710, 651 cmꢂ1; 1H NMR (400 MHz, CDCl3):
d 7.50 (m,
49.6, 25.7; Anal. Calcd for C11H12N2S: C, 64.67; H, 5.92; N, 13.71;
found C, 64.71; H, 5.95; N, 13.68.
1H, Ar. CeH), 7.31 (d, 1H, J¼8 Hz, Ar. CeH), 7.03 (t, 1H, J¼9 Hz, Ar.
CeH), 3.80e3.82 (m, 4H, aliphaticeCH2e), 3.57 (t, 4H, J¼4.8 Hz,
aliphaticeCH2e); 13C NMR (100 MHz, CDCl3):
d 168.7, 159.5, 157.1,
4.2.4. 2-(4-Phenylpiperazin-1-yl)benzo[d]thiazole (1d0). The gen-
eral procedure was followed. The product was purified by column
chromatography (10% EtOAc/hexane) to give the title compound
1d0 (221 mg, 75%) as white solid; Rf (10% EtOAc/hexane) 0.24; mp
170 ꢀC; nmax (KBr): 3026, 2861, 1594, 1560, 1539, 1503, 1443, 1384,
149.0, 131.3, 119.9, 119.8, 114.0, 113.8, 107.7, 107.5, 66.6, 48.5; HRMS
(ESI) calcd for C11H11N2OFS (MþHþ) 239.0649, found 239.0651.
4.2.9. 4-(6-Bromobenzo[d]thiazol-2-yl)morpholine (4a0). The gen-
eral procedure was followed. The product was purified by column
chromatography (10% EtOAc/hexane) to give the title compound 4a0
(222 mg, 75%) as white solid; Rf (10% EtOAc/hexane) 0.25; mp
165e167 ꢀC; nmax (KBr): 2918, 2857, 1591, 1535, 1443, 1372, 1280,
1347, 1293, 1249, 1229, 1194, 1158, 1024, 935, 755 cmꢂ1
(400 MHz, CDCl3):
;
1H NMR
d
7.62 (d, 2H, J¼8.0 Hz, Ar. CeH), 7.33 (m, 3H,
Ar. CeH), 7.10 (t, 1H, J¼8.0 Hz, Ar. CeH), 6.94 (m, 3H, Ar. CeH),
3.78 (t, 4H, J¼5.2 Hz, aliphaticeCH2e), 3.29 (t, 4H, J¼5.2 Hz,
1258, 1229, 1110, 1026, 940, 863, 813 cmꢂ1
CDCl3):
J¼4.8 Hz, aliphaticeCH2e), 3.57 (t, 4H, J¼4.8 Hz, aliphaticeCH2e);
;
1H NMR (400 MHz,
aliphaticeCH2e); 13C NMR (100 MHz, CDCl3):
d
168.7, 152.8,
d 7.68 (s, 1H, Ar. CeH), 7.37 (s, 2H, Ar. CeH), 3.80 (t, 4H,
151.0, 130.9, 129.3, 126.2, 121.7, 120.8, 120.7, 119.3, 116.9, 49.1,